Morbidity in pediatric burns, toxic shock syndrome, and antibiotic prophylaxis: a retrospective comparative study

Stephen Mulgrew1, Anna Khoo, Rufus Cartwright

  • 1From the *Department of Plastic Surgery, Lister Hospital, Coreys Mill Lane, Stevenage; †Department of Plastic Surgery, Addenbrookes Hospital, Cambridge; Departments of ‡Urogynaecology, and §Epidemiology & Biostatistics, Imperial College London, London; and ∥Department of Plastic Surgery, Salisbury Hospital Odstock, Salisbury, UK.

Annals of Plastic Surgery
|September 24, 2013
PubMed

Insights

Routine prophylactic antibiotics for pediatric burns do not reduce toxic shock syndrome or morbidity. Antibiotic use should be based on individual patient symptoms, not as a standard preventative measure.

Area of Science:

  • Pediatric Burn Care
  • Infectious Disease Management
  • Clinical Protocol Evaluation

Background:

  • Prophylactic antibiotic use in pediatric burns has been proposed to decrease toxic shock syndrome.
  • Clinical practice regarding antibiotic administration for burns varies, necessitating evidence-based guidelines.
  • Evaluating established protocols is crucial for optimizing patient outcomes and resource allocation.

Purpose of the Study:

  • To investigate the efficacy of routine prophylactic antibiotic administration in pediatric burn patients.
  • To compare morbidity and the incidence of toxic shock syndrome between groups receiving prophylactic versus on-demand antibiotics.
  • To determine if routine antibiotic prophylaxis is a necessary intervention for pediatric burn cases.

Main Methods:

  • Retrospective review of 1250 pediatric burn cases spanning 16 years (1983-1999).
  • Division of patients into two groups: control (antibiotics as clinically indicated) and cases (routine prophylactic antibiotics post-1991).
  • Analysis of clinical data to assess differences in morbidity and signs of toxic shock syndrome between the groups.

Main Results:

  • No statistically significant difference was observed in morbidity rates between the prophylactic antibiotic group and the control group.
  • The incidence of signs suggestive of toxic shock syndrome did not differ significantly between the two treatment protocols.
  • Findings indicate that routine prophylactic antibiotic use did not confer additional clinical benefits in this pediatric burn cohort.

Conclusions:

  • Routine prophylactic antibiotic administration is not necessary for pediatric burn patients.
  • Antibiotic prescribing for pediatric burns should be guided by clinical presentation and individual patient assessment.
  • This study supports a targeted, symptom-based approach to antibiotic use, avoiding unnecessary prophylaxis.

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Burn Injuries01:22

Burn Injuries

Burn injuries occur when the skin and underlying tissues are damaged due to exposure to heat, electricity, chemicals, radiation, or friction. They can vary in severity, from minor superficial burns to severe deep burns that can be life-threatening.
The damage results in the death of skin cells, which can lead to a massive loss of fluid. Dehydration, electrolyte imbalance, and renal and circulatory failure follow, which can be fatal. Burn patients are treated with intravenous fluids to offset...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmaceutical Poisoning: Potential Scenarios01:26

Pharmaceutical Poisoning: Potential Scenarios

Pharmaceutical poisoning can occur through various channels, impacting an estimated 2 million hospitalized patients in the U.S. annually with serious adverse drug responses. These scenarios encompass both therapeutic uses, such as drug toxicity, where even standard dosages can lead to severe central nervous system depression, and non-therapeutic exposures, including accidental ingestion by children, and environmental and occupational exposures.Unintentional poisonings often involve exploratory...
Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...